Ahn Joong Kyong, Lee You Sun, Jeon Chan Hong, Koh Eun-Mi, Cha Hoon-Suk
Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Kangnam-Gu, Seoul, South Korea.
Clin Rheumatol. 2008 Feb;27(2):201-5. doi: 10.1007/s10067-007-0685-z. Epub 2007 Jul 17.
The aim of this study was to compare the efficacy of immunosuppressive therapy alone with that of combination therapy involving immunosuppressants and anticoagulation for the treatment of venous thrombosis in Behcet's disease (BD). A retrospective analysis was made of 37 patients with venous thrombosis in BD. BD patients with venous thrombosis were divided into three groups: one group (N = 16) received immunosuppressive therapy alone, another group (N = 17) received immunosuppressant and anticoagulation combination therapy, and the third group (N = 4) received anticoagulation therapy only. Clinical and laboratory parameters and the recurrence of venous thrombosis were assessed. Venous thrombosis in BD appeared to have a more diffuse pattern than idiopathic type and a predilection for lower limbs. The most commonly involved sites were the superficial and common femoral veins. Recurrence of venous thrombosis occurred in two cases in the immunosuppressant group (12.5%), one case in the combination therapy group (5.9%), and three cases in the anticoagulant group (75%). No significant difference was found between recurrence in the immunosuppressant and combination therapy groups. Acute phase reactants were elevated in all six patients at the time of venous thrombosis recurrence. Our study suggests that immunosuppressive therapy is essential and that anticoagulation therapy might not be required for the treatment of deep venous thrombosis associated with BD.
本研究旨在比较单独免疫抑制治疗与免疫抑制剂联合抗凝治疗白塞病(BD)静脉血栓形成的疗效。对37例BD合并静脉血栓形成的患者进行回顾性分析。BD合并静脉血栓形成的患者分为三组:一组(N = 16)仅接受免疫抑制治疗,另一组(N = 17)接受免疫抑制剂与抗凝联合治疗,第三组(N = 4)仅接受抗凝治疗。评估临床和实验室参数以及静脉血栓形成的复发情况。BD患者的静脉血栓形成似乎比特发性类型具有更广泛的模式,且下肢受累更常见。最常累及的部位是浅静脉和股总静脉。免疫抑制治疗组有2例(12.5%)发生静脉血栓形成复发,联合治疗组有1例(5.9%)复发,抗凝治疗组有3例(75%)复发。免疫抑制治疗组与联合治疗组的复发率无显著差异。在静脉血栓形成复发时,所有6例患者的急性期反应物均升高。我们的研究表明,免疫抑制治疗至关重要,且治疗与BD相关的深静脉血栓形成可能不需要抗凝治疗。